GOVERNMENT-OF-COMOROS
23.11.2021 06:02:14 CET | Business Wire | Press release
Under the patronage of the President of the Comoros, Azali Assoumani, the Comoros organized a business forum on the sidelines of Expo Dubai 2020, on Tuesday, November 9, 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211122005863/en/
This forum was part of the strengthening of economic relations between the Comoros and its partners, in the continuity of the Conference of Development Partners (CPAD), which took place in December 2019, on the eve of the pandemic of COVID-19.
To become an emerging country by 2030, the Comoros will rely on the strong involvement of international companies. The Comoros are strategically located in the Mozambique Channel, and have strong telecom connectivity with the presence of four fiber optic cables, as well as reforms to improve the business climate.
The objective of this forum was to invite companies recognized in their sector to establish themselves in the Comoros, with a view to accelerating the realization of the Comoros Emerging Plan projects and participating in the creation of long-term jobs.
The event saw the participation of nearly 70 businessmen and women from around 15 countries, including the United Arab Emirates, France, Madagascar, Russia, Saudi Arabia, Turkey and Mauritius.
The business forum was marked by five speeches: First, Minister of Economy and Investments, Mze Aboudou MOHAMED CHANFIOU, opened the ceremony; then Executive Secretary of CPAD, Assoumani ABDOUSALAM, introduced the “Comoros Emerging Plan” which will transform the Comoros by 2030; then Director General of the National Agency for the Promotion of Investments, Ms. Nadjat SOIDIKI, has presented the reforms undertaken to improve the business climate; follow Minister of Agriculture, Fisheries, Environment, Tourism and Handicrafts, Houmed MSAIDIE, highlighted tourism and agriculture opportunities. Finally, President AZALI closed the speeches by recalling the central place given to the private sector in the transformation of the Comoros.
During the B2B session which lasted 2 hours, twenty-nine business meetings were held in addition to the other informal discussions held outside the B2B rooms.
At the end of the forum, the following results were recorded, in particular the establishment of contact between the Comorian authorities and international entrepreneurs, the networking between Comorian and foreign companies, and the identification of 10 projects to be launched in the 12 months.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122005863/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom